Fidelity
Home > Boards > US OTC > Delisted > Asyst Technologies, Inc. (fka ASYTQ)

This whole case interests me from a learning perspective,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
trader53 Member Profile
Member Level 
Followed By 1,598
Posts 39,317
Boards Moderated 6
Alias Born 06/04/09
160x600 placeholder
Johnson & Johnson Earnings Rise 35%
Johnson & Johnson earns $4.73 billion, or $1.64 a share, led by continued sales growth in its pharmaceutical business. Revenue increased 3.5% to $18.12 billion. It also lifted its EPS estimate range for the year.
More Top Equities Stories Of The Day
GM's Barra Unveils Further Plans to Improve Safety
Glencore Xstrata Buys Caracal -- Update
Citi Picks Dewilde to Lead Asia Markets and Investor Services Business
Sales of Johnson s New Hepatitis Drug Soars
Twitter Co-Founders, CEO Won't Sell Shares -- 2nd Update
Columnist Joanna Stern answers readers' technology questions
Surgical Device Maker ConMed Exploring Sale -Reuters
Yahoo Shows Signs of Growth
trader53 Member Level  Monday, 02/13/12 09:22:46 AM
Re: $tockKing post# 2824
Post # of 2842 
This whole case interests me from a learning perspective,
in addition to the shares I had bought. Just by following the events, I have learned a lot, and that is worth the time that I have spent watching and reading about it.

I'll continue to follow it, until I see the words "Case Closed", I think.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist